WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

A new journal where molecular biology meets clinical research

Details
Research
17 October 2008
The European Molecular Biology Organization (EMBO) has announced the introduction of EMBO Molecular Medicine, a new journal dedicated to a research discipline focused on the interface between molecular biology and clinical research. The new journal, launching in 2009, will publish original research offering molecular insights into cellular and systemic processes underlying defined human diseases as well as potential clinical applications for diagnosis, prevention and therapy.
Read more ...

EMEA half-year report for 2008 shows activities to be on target

Details
Research
11 October 2008
The European Medicines AgencyAt its 60th meeting, held in London on 2 October 2008, the Management Board of the European Medicines Agency (EMEA) welcomed the half-year report for 2008 presented to them by EMEA Executive Director Thomas Lönngren.
Read more ...

New Media Offers Cost-Efficient Ways to Reach and Engage Targets

Details
Research
09 October 2008
Manhattan ResearchOver 145 million U.S. adults use the Internet to research health information, according to pharmaceutical and healthcare market research company Manhattan Research. The company has just released Cybercitizen Health v8.0, a multi-client study and strategic advisory service focused on how consumers use media and technology for health information and its impact on treatment and product decisions.
Read more ...

Medicines regulators on both sides of the Atlantic confirm commitment to cooperation on medicines

Details
Research
09 October 2008
The European Commission (EC), the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) have affirmed their commitment to regulatory cooperation and to intensifying their interactions in several new areas.
Read more ...

Philips develops ultrasound-activated microbubbles for localized delivery of cancer drugs

Details
Research
06 October 2008
Philips is developing an ultrasound-based drug delivery technology that is designed to increase the effectiveness and reduce the side effects of chemotherapy treatment for certain types of cancer. The system proposes the use of drug-loaded microbubbles, no larger than red blood cells, that can be injected into the patient's bloodstream, tracked via ultrasound imaging, and then ruptured by a focused ultrasound pulse to release their drug payload when they reach the desired spot.
Read more ...

Pharmaceutical Forum Concluded Successfully

Details
Research
04 October 2008
ECThe final report of the Pharmaceutical Forum has been presented in Brussels setting out principles and recommendations on three key challenges in the pharmaceutical landscape. Firstly, how to improve information on diseases and treatments, secondly, how to compare medicines and identify the most effective ones and thirdly how to balance access and reward for innovation within limited healthcare budgets.
Read more ...

FDA Analysis on Cholesterol Lowering Medications

Details
Research
01 October 2008
U.S. Food and Drug AdministrationA U.S. Food and Drug Administration's analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as "Lou Gehrig's Disease." The analysis was reported on Monday, Sept. 29, 2008 in Pharmacoepidemiology and Drug Safety.
Read more ...

More Pharma News ...

  1. Life Competence - the first global picture on the EU-funded health research
  2. European Consumers' Tools to Retrieve Health Information Online
  3. A New Computer-Modelling Tool to Improve Psoriasis Management and Treatment Outcomes
  4. Genzyme Marks Grand Opening of New Science Center
  5. A project coordinated by VTT turns plant cells into medical factories
  6. New EudraLex CD v 18 CD with the Pharmaceutical Legislation now available for download
  7. Top Pharmaceutical Websites Visited by European Consumers Revealed
  • Start
  • Prev
  • 292
  • 293
  • 294
  • 295
  • 296
  • 297
  • 298
  • 299
  • 300
  • 301
  • Next
  • End
Tahmeena

Business & Industry

  • Pfizer reports record full-year 2022 results
  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Research & Development

  • Scientists pinpoint protein that helps cancer-causing viruses evade immune response
  • Transforming the way cancer vaccines are designed and made
  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.